Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis

M Moretti, M T Lopez-Vidriero, D Pavia, S W Clarke

Abstract

Background – Patients with chronic bronchitis show a large intersubject variation in sputum rheology, tracheobronchial clearance, and reversibility of airflow obstruction to \( \beta_2 \) agonists. The bronchial mediators which are known to cause bronchoconstriction, mucosal oedema, mucus hypersecretion, and cough can also affect mucociliary transport. The aim of this study was to ascertain whether changes in tracheobronchial clearance and sputum rheological properties in patients with chronic bronchitis were associated with a specific degree of airflow reversibility assessed as the bronchial response to an inhaled \( \beta_2 \) agonist (fenoterol 400 \( \mu \)g).

Methods – Bronchial reversibility (percentage change in baseline forced expiratory volume in one second (FEV\(_1\))) was measured in 26 patients with chronic bronchitis on three separate occasions, at least one week apart. Tracheobronchial clearance was evaluated by a non-invasive radioaerosol technique, and an oscillatory viscometer was used for measuring sputum apparent viscosity and elasticity. The number of coughs (productive and non-productive coughs), the wet weight of sputum, and its radioaerosol content were recorded during the six hour clearance period, as well as the 24 hour sputum production.

Results – The change in FEV\(_1\) after fenoterol was less than 15% in 12 patients and more than 15% in 14. Patients with airways reversibility of more than 15% had faster tracheobronchial clearance, more coughs, lower sputum viscosity and elasticity, and larger 24 hour sputum production than those with airways reversibility of less than 15%.

Conclusions – In patients with chronic bronchitis a large bronchodilator response is associated with faster clearance of mucus by mucociliary transport and coughing.

(Thorax 1997;52:176–180)

Keywords: bronchial reversibility, chronic bronchitis, cough, rheology, sputum, tracheobronchial clearance.

Patients with chronic bronchitis have a wide range of impairment of tracheobronchial clearance and of the rheological properties of secretions. Furthermore, many have decreased airway obstruction after inhalation of \( \beta_2 \) agonists which is sometimes as great as that found in asthma. The bronchial mediators which are known to cause bronchoconstriction, mucosal oedema, mucus hypersecretion, and cough can also affect mucociliary transport, but no information is available on the distribution and on the relationship between reversibility of airflow obstruction and the impairment of tracheobronchial clearance in chronic bronchitis.

Hypothetically, patients with chronic bronchitis who have a substantial bronchodilator response might show some characteristics of bronchial asthma such as higher values for the viscoelastic properties of sputum and greater impairment of tracheobronchial clearance.

The aim of this study was to ascertain whether the degree of bronchial reversibility in patients with chronic bronchitis was associated with changes in tracheobronchial clearance and sputum rheological properties in two groups selected on the basis of the bronchodilator response to a \( \beta_2 \) agonist of more or less than 15% of the baseline forced expiratory volume in one second (FEV\(_1\)).

Methods

PATIENTS

Twenty-six patients (23 men) with airways obstruction (FEV\(_1\) < 70% predicted), who fulfilled the criteria of chronic bronchitis according to the UK Medical Research Council’s definition, were included in the study. All remained clinically stable throughout the study period.

PULMONARY FUNCTION TESTS

In each patient baseline pulmonary function tests comprising forced vital capacity (FVC), forced expiratory volume in one second (FEV\(_1\)), maximum mid expiratory flow rate at 25–75% of FVC (MMFR\(_{25–75}\)) were measured using a dry bellows spirometer (Vitalograph) and peak expiratory flow rate (PEFR) was measured with a Wright peak flow meter.

BRONCHODILATOR RESPONSE

The patients withheld their inhaled bronchodilator therapy and oral theophylline for the preceding six hours. The FEV\(_1\) was measured three times and the highest of three technically acceptable readings was recorded. The measurements were repeated 20 minutes after in-
halting two puffs of fenoterol (400 µg) from a metered dose inhaler, with a one minute interval between puffs. The bronchodilator response was evaluated as the percentage change in FEV₁ from the baseline value (pre-bronchodilator inhalation value).

Reversibility was assessed three times in each patient, always on a different day from the tracheobronchial clearance measurement. In 16 patients, these assessments were carried out at monthly intervals the day before the measurements of tracheobronchial clearance were conducted. In the remaining 10 patients, in whom only one reversibility test was carried out at the time the tracheobronchial clearance was measured, the bronchodilator response was assessed further at weekly intervals in order to confirm the previous observations. Based on the mean level of reversibility subsequently assessed, the patients were divided into two groups in accordance with most of the studies on bronchodilator response after β agonist inhalation in chronic bronchitis.¹³-¹⁰ Patients with bronchial reversibility of <15% (group 1) and those with bronchial reversibility of 15% or more (group 2). An improvement of 15% over the initial FEV₁ after the β agonist challenge was taken as evidence of reversible airway obstruction.¹¹,¹²

The study was approved by the local ethics committee and all patients gave written informed consent for participating in the study.

TRACHEOBRONCHIAL CLEARANCE

A radioaerosol technique was used to measure tracheobronchial clearance in a non-invasive manner, as previously described in detail.⁷ Each patient discontinued all the bronchodilator therapies six hours before the measurement of tracheobronchial clearance. The subjects inhaled 5 µm polystyrene particles labelled with the radionuclide technetium-99m using a standardised procedure.¹³ Radioactivity in the lung was measured by suitably collimated anterior and posterior scintillation counters immediately after inhalation at 30 minute intervals for six hours and a final count was made at 24 hours. The lung burden at 24 hours, expressed as percentage of the initial deposited radioactivity, was taken to represent alveolar deposition (AD) – that is, the amount of radioactivity deposited in the non-ciliated airways and alveoli. The initial topographical distribution of the radioaerosol within the lung was assessed with a large field of view gamma camera (International General Electric) interfaced with a computer and the lung margins were delineated by a ventilatory scan with krypton-81m gas. The penetration index (PI) was defined as the ratio of peripheral to central zone radioactivity for the radioaerosol relative to that of ⁸¹Kr gas.¹⁴

Tracheobronchial clearance at six hours after inhalation was expressed as the percentage of the initial tracheobronchial deposition retained at six hours and corrected for productive coughing by adding the radioactivity measured in the sputum to the observed retention curve at the time when it was produced.¹⁵ In fact, cough accelerating the movement of the radioaerosol particles in the airways, modifying the physiological process of the radioaerosol clearance by the ciliated system. A more useful and accurate way of expressing the results is by calculating the area under the tracheobronchial clearance curve (AUC) using the trapezoidal rule – a large AUC indicates slow tracheobronchial clearance and a small AUC indicates fast tracheobronchial clearance. We divided the six hour tracheobronchial clearance measurement into two periods since this is a more useful and accurate way of expressing the results.¹⁶ A six hour period is sufficient to achieve complete clearance of the radioaerosol in normal subjects but patients with chronic bronchitis in whom mucociliary clearance is impaired require a period longer than six hours to achieve a complete clearance. Since observations cannot be prolonged for more than six hours for practical reasons, the division of AUC into two periods allows the process of clearance to be followed better. Hence, the tracheobronchial clearance was expressed at three different time intervals: 0–3 hours (AUC 0–3 h), 3–6 hours (AUC 3–6 h), and 0–6 hours (AUC 0–6 h).

To avoid changes in radioaerosol deposition, tracheobronchial clearance measurements were done on the day after the reversibility studies when the patients were stable. In 10 patients, measurement of their tracheobronchial clearance was carried out twice over a one year period and in one patient three times. In patients with more than one measurement of tracheobronchial clearance the results were expressed as the arithmetical mean.

During the tracheobronchial clearance runs the number of coughs was recorded as well as the wet weight and the radioactive content of all the sputum samples.

SPUTUM RHEOLOGICAL STUDIES

Apparent viscosity and elasticity were measured using a Contraves Low Shear 30 sinus viscometer at a frequency of 0.352 Hz. The sputum samples produced during the first three hours of the tracheobronchial clearance observations were studied. When more than one sample was produced the arithmetical mean was obtained. In the 11 patients who underwent the tracheobronchial clearance run on two or three occasions during a one year period, the viscoelastic results were expressed as the arithmetical mean.

DAILY SPUTUM PRODUCTION

Each patient collected the sputum produced during the 24 hours before the tracheobronchial clearance assessment and the amount was recorded as wet weight.

DATA ANALYSIS

The Student’s t test for unpaired data was used in the statistical analysis.
Results

Patients
The mean (SE) physical characteristics, smoking habits, baseline lung function indices, AD and PI values are given in table 1. Fourteen patients were current smokers and 12 had ceased smoking at least one year before the study. Both smokers and ex-smokers were matched well in groups 1 and 2.

Bronchial Reversibility
Twelve of the 26 patients (46%) were in group 1 and 14 (54%) in group 2. There was a trend for the observed FEV₁ pre-reversibility to be higher in group 1 (1.42 (0.16) l) than in group 2 (1.09 (0.08) l) but this was not statistically significant. After reversibility the FEV₁ was also not significantly higher in group 1 (1.58 (0.19) l) than in group 2 (1.34 (0.05) l). The percentage change after fenoterol was +10.3 (0.9)% and +26.6 (2.0)%, respectively, for groups 1 and 2 (p<0.001). There was a low intra-patient coefficient of variation (<10%) in the bronchial reversibility test among the patients included in the study.

Tracheobronchial Clearance
The six hour tracheobronchial clearance results are shown in table 2. The tracheobronchial clearance was slower in group 1 than in group 2. AUC 0–6 was smaller in group 2 (350 (20)%/hour, indicating a faster clearance) than in group 1 (390 (19)%/hour), although the difference did not reach statistical significance. The values of AUC between 0–3 hours and 3–6 hours were always greater in group 1 than in group 2, the difference being significant for 3–6 hours (p<0.05).

Cough
Patients with bronchial reversibility of >15% coughed more than those with bronchial reversibility of <15% but no statistical difference between the two groups was observed in the mean value of total number of coughs for the three observation periods. The mean number of coughs in the three observation periods for the two groups is given in table 2.

Sputum Production and Sputum Rheological Properties
Five patients (two in group 1 and three in group 2) of the 26 did not produce sputum during the six hour observation period. Apparent viscosity (p<0.05) and elasticity (p<0.02) were both significantly lower in group 2 than in group 1.

Discussion
The results of this study indicate that patients with chronic bronchitis who have airway reversibility of >15% of baseline FEV₁ differ from those with bronchial reversibility of <15% in having a higher number of coughs, more bronchial hypersecretion, lower sputum rheological properties, and faster tracheobronchial clearance.

The data relating to bronchial reversibility observed in our patients with chronic bronchitis are in agreement with those reported by other authors in that a large proportion had a bronchodilator response to a β₂ agonist similar to that of asthmatics. As expected, the patients had a wide range of impairment of tracheobronchial clearance and of rheological properties of the sputum.12 Although the tracheobronchial clearance was markedly impaired in both groups compared with healthy

Table 1 Mean (SE) physical characteristics, smoking habits, baseline lung function indices, AD and PI values are given in table 1. Fourteen patients were current smokers and 12 had ceased smoking at least one year before the study. Both smokers and ex-smokers were matched well in groups 1 and 2.

<table>
<thead>
<tr>
<th>Group 1 (n=12)</th>
<th>Group 2 (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>No. of women</td>
<td>70 (3)</td>
</tr>
<tr>
<td>Pack years</td>
<td>1</td>
</tr>
<tr>
<td>FEV₁ (% pred)</td>
<td>60 (7)</td>
</tr>
<tr>
<td>PEF (%)</td>
<td>54 (6)</td>
</tr>
<tr>
<td>FVC (% pred)</td>
<td>84 (9)</td>
</tr>
<tr>
<td>MPR₂₅₋₇₅ (%)</td>
<td>23 (4)</td>
</tr>
<tr>
<td>FEV₁ (% change after fenoterol)</td>
<td>10.3 (0.9)</td>
</tr>
<tr>
<td>AD (%)</td>
<td>27 (12)</td>
</tr>
<tr>
<td>PI</td>
<td>0.43 (0.29)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; MPR₂₅₋₇₅ = maximum mid expiratory flow at 25–75% of FVC.

Table 2 Mean (SE) results of tracheobronchial clearance measurements (AUC), number of coughs, sputum rheological properties, and sputum production for patients with chronic bronchitis with bronchial reversibility of <15% (group 1) and >15% (group 2).

<table>
<thead>
<tr>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC</td>
<td></td>
</tr>
<tr>
<td>0–6 hours</td>
<td>390 (19)</td>
</tr>
<tr>
<td>0–3 hours</td>
<td>251 (13)</td>
</tr>
<tr>
<td>3–6 hours</td>
<td>188 (8)</td>
</tr>
<tr>
<td>Total coughs (n)</td>
<td>14.1 (3.0)</td>
</tr>
<tr>
<td>0–6 hours</td>
<td>9.0 (2.1)</td>
</tr>
<tr>
<td>3–6 hours</td>
<td>5.9 (1.3)</td>
</tr>
<tr>
<td>Sputum production (g) daily</td>
<td>2.8 (0.8)</td>
</tr>
<tr>
<td>Sputum rheological properties</td>
<td></td>
</tr>
<tr>
<td>Viscosity (mPa.s)</td>
<td>646 (89)</td>
</tr>
<tr>
<td>Elasticity (mPa)</td>
<td>3721 (686)</td>
</tr>
</tbody>
</table>

*p<0.05; **p<0.02.
controls, patients in group 2 cleared better than those in group 1. The AUC at the different time intervals was smaller in group 2 than in group 1, especially in the 3–6 hour period. The faster clearance of the radioaerosol in group 2 progressively increased the difference in airway radioaerosol retention between the two groups. Hence the difference between groups 1 and 2 progressively increased with time, becoming significant in the last three hours of the six hour observation period. This difference in tracheobronchial clearance between the two groups was not attributable to differences in the initial topographical distribution of the radioaerosol since the mean values of alveolar deposition and penetration index were similar in both groups.

Patients with bronchial reversibility of >15% coughed more and produced a larger amount of mucus with a higher radionuclide content than those with bronchial reversibility of <15%, especially at 3–6 hours but not at 1–2 hours. The mean values of alveolar radioaerosol retention between the two groups. Bronchodilator response in chronic obstructive disease.

The rheological values of the sputum of the 26 patients had a wide range; this is in agreement with previous studies but, despite this, the mean value of sputum viscosity and elasticity were significantly higher in patients in group 2 than those in group 1. This difference in sputum viscoelastic properties could contribute partially to the difference in tracheobronchial clearance between the two groups. In vitro studies using the frog palate preparation have shown that the transport rate of human sputum samples is influenced by the mucus rheological properties, especially elasticity.

Furthermore, in patients with chronic bronchitis a significant positive correlation was reported in vivo between tracheobronchial clearance and the relative transport of sputum measured on the ciliated frog palate preparation.

Patients in group 2 also differed from those in group 1 in producing more sputum within the six hour tracheobronchial clearance measurement as well as in the 24 hour collection. The greater sputum production could contribute to the faster tracheobronchial clearance in group 2 since a significant positive correlation has been reported between tracheobronchial clearance and sputum production in patients with chronic bronchitis.

These results indicate that differences in bronchial reversibility are associated with various degrees of mucus clearance in chronic bronchitis. These data are supported by the fact that inflammatory mediators are known to influence both the mechanisms involved in tracheobronchial clearance such as mucus secretion, ciliary activity, coughing, and bronchial reversibility. Further studies are indicated to ascertain whether the degree of inflammation and the related mediators or the type of cellular components are the contributing factors.

References:


